Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.59 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.35 |
| ▸ | GSR | P00390 | 2/20 | 0.34 |
| ▸ | P2RY10 | O00398 | 3/20 | 0.33 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.33 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352049 | 0.90 | SLC1A5 (0.43) | PTGS1SLC7A11SLC1A5NOS3NOS1 | |
| SCHEMBL3502798 | 0.90 | SLC1A5 (0.43) | PTGS1SLC7A11SLC1A5NOS3NOS1 | |
| Glycine SCHEMBL8588130 | 0.86 | GLRA1 (0.42) | PTGS1SLC7A11SLC1A5NOS3NOS1 | |
| SCHEMBL3075848 | 0.86 | PTGS1 (0.43) | PTGS1SLC7A11SLC1A5NOS3NOS1 | |
| SCHEMBL4752999 | 0.85 | SLC1A5 (0.40) | PTGS1SLC7A11SLC1A5NOS3NOS1 | |
| SCHEMBL12500454 | 0.85 | SLC1A5 (0.40) | PTGS1SLC7A11SLC1A5NOS3NOS1 | |
| SCHEMBL16058499 | 0.84 | PTGS1 (0.48) | PTGS1SLC7A11SLC1A5NOS3NOS1 | |
| Cysteine SCHEMBL15417922 | 0.84 | PTGS1 (0.42) | PTGS1SLC7A11SLC1A5NOS3NOS1 | |
| Alanine SCHEMBL5168125 | 0.83 | SLC7A5 (0.42) | PTGS1SLC7A11SLC1A5NOS3NOS1 | |
| Serine SCHEMBL7925097 | 0.83 | SLC1A5 (0.42) | PTGS1SLC7A11SLC1A5NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571897-B1 | NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE | BETTA PHARMACEUTICALS CO LTD (CN) | 2014-11-05 | — | — | EP | claimed |
| US-20130203672-A1 | Novel Glucagon Like Peptide Analogs, Composition, and Method of Use | BETTA PHARMACEUTICALS CO., LTD (CN) | 2013-08-08 | — | — | US | claimed |
| EP-2571897-A1 | NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE | Zhejiang Beta Pharma Inc. (CN) | 2013-03-27 | — | — | EP | claimed |
| WO-2011143788-A1 | NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE | ZHEJIANG BETA PHARMA INC. (CN) | 2011-11-24 | — | — | WO | claimed |
| US-20210116462-A1 | Methods and Compositions for the Diagnosis and Treatment of Kawasaki Disease | MOMENTA PHARMACEUTICALS, INC. | 2021-04-22 | — | — | US | disclosed |
| CN-110317766-B | Genetically engineered bacterium capable of highly producing L-cysteine, construction method and application | 浙江工业大学 | 2020-08-28 | — | — | CN | disclosed |
| EP-3137907-A2 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF KAWASAKI DISEASE | Momenta Pharmaceuticals, Inc. (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20170052200-A1 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF KAWASAKI DISEASE | MOMENTA PHARMACEUTICALS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9487570-B2 | Glucagon like peptide analogs, composition, and method of use | BETTA PHARMACEUTICALS CO., LTD (CN) | 2016-11-08 | — | — | US | disclosed |
| WO-2016161333-A2 | COMPOSITIONS COMPRISING BIOCONJUGATES | PURDUE RESEARCH FOUNDATION (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2015168602-A2 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF KAWASAKI DISEASE | MOMENTA PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| EP-2571897-B1 | NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE | BETTA PHARMACEUTICALS CO LTD (CN) | 2014-11-05 | — | — | EP | disclosed |
| US-20130203672-A1 | Novel Glucagon Like Peptide Analogs, Composition, and Method of Use | BETTA PHARMACEUTICALS CO., LTD (CN) | 2013-08-08 | — | — | US | disclosed |
| EP-2571897-A1 | NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE | Zhejiang Beta Pharma Inc. (CN) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011143788-A1 | NOVEL GLUCAGON LIKE PEPTIDE ANALOGS, COMPOSITION, AND METHOD OF USE | ZHEJIANG BETA PHARMA INC. (CN) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203672-A1 | Novel Glucagon Like Peptide Analogs, Composition, and Method of Use | IAPP, GLP1R, GIPR | PTGS1 3042/4885SLC7A11 1980/4885SLC1A5 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.